Ann: Becoming a substantial holder, page-3

Hi Sol,

Certainly appears to be a tightly controlled share price these days. No idea about the increase in volume but may have something to do with the recent excise of approx $13m options @27c. Maybe some cashing in, but then still need a buyer.

Bioshares have provided extensive coverage in recent times including yet another update about a week ago. They are quite bullish on the potential of Opt-302 and where it sits within the framework of current and prospective therapies going forward. They are expecting significant investment interest in the second half of 2019 given the company is 5 months ahead of it’s original reporting timeframe for it’s phase 2b trial.

Cheers Yehudi